Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NWA0
UPID:
MED9_HUMAN
Alternative names:
Mediator complex subunit 9
Alternative UPACC:
Q9NWA0
Background:
Mediator of RNA polymerase II transcription subunit 9, also known as Mediator complex subunit 9, plays a pivotal role in the transcription of RNA polymerase II-dependent genes. It acts as a crucial coactivator by facilitating the transfer of information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. This protein is essential for the assembly of a functional preinitiation complex, incorporating RNA polymerase II and general transcription factors.
Therapeutic significance:
Understanding the role of Mediator of RNA polymerase II transcription subunit 9 could open doors to potential therapeutic strategies.